“…TZDs are a class of insulin sensitizing drugs, which include ciglitazone, pioglitazone, troglitazone and rosiglitazone [15]. TZDs are known to stimulate PPAR-γ receptor, they also have multiple PPAR-γ independent biological profiles, such as antimalarial [16], antioxidant [17], antitumor [18], cytotoxic [19], anti-inflammatory [20], antimicrobial [21], radical scavenger [22], glycogen synthase kinase (GSK) 3 inhibitor [23], chymase inhibitor [24], aldose reductase inhibitor [25], cholesterol esterase inhibitor [26], thyroid hormone receptor antagonist [27] and neuroprotective [28].…”